止咳平喘十二味合剂联合乌苯美司胶囊对急性加重期慢性阻塞性肺疾病病人氧合指数、免疫失衡及炎性因子的影响  

Effects of Zhike Pingchuan twelve mixture combined with ubenimex capsule on oxygenation index,immune imbalance and inflammatory factors in patients with COPD

作　　者：赵丽丽 王青霞 ZHAO Lili;WANG Qingxia(Department of Respiratory and Critical Medicine,Tongchuan People's Hospital,Tongchuan,Shaanxi 727000,China)

机构地区：[1]铜川市人民医院呼吸与危重医学科,陕西铜川727000

出　　处：《安徽医药》2021年第12期2519-2522,共4页Anhui Medical and Pharmaceutical Journal

基　　金：陕西省教育厅专项科研计划项目(16JK2031)。

摘　　要：目的分析止咳平喘十二味合剂联合乌苯美司胶囊对急性加重期慢性阻塞性肺疾病(慢阻肺)病人氧合指数、免疫失衡及炎性因子的影响。方法选取铜川市人民医院2019年1月至2020年3月收治的60例急性加重期慢阻肺病人作为研究对象。按随机数字表法分为两组,对照组30例,采用常规治疗+乌苯美司胶囊口服(3次/天,10毫克/次);观察组30例,在对照组基础上加用止咳平喘十二味合剂(2次/天,1袋/次,餐后30 min口服)。两组均连续治疗8周。观察并记录两组治疗前后氧合指数、慢阻肺症状(CAT)评分、6 min步行试验(6MWD)、免疫功能指标(包括CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+))、炎性因子[白细胞介素-8(IL-8)、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)]及肺功能指标[包括用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))及FEV_(1)/FVC],然后进行统计学分析。结果两组治疗后氧合指数、CAT评分及6MWD均明显改善,但观察组显著更优(P<0.05),其中对照组治疗后氧合指数为(221.77±20.76),观察组为(245.65±19.76);两组治疗后CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)明显升高,CD8^(+)明显下降,但观察组明显优于对照组(P<0.05),其中对照组治疗后CD3^(+)、CD4^(+)/CD8^(+)分别为(60.71±4.82)%、(0.97±0.34),观察组分别为(67.75±4.71)%、(1.38±0.23);两组治疗后IL-8、TNF-α及CRP均显著下降,且观察组IL-8(17.63±4.01)ng/L、TNF-α(38.59±6.13)ng/L及CRP(15.14±2.24)mg/L明显低于对照组的(22.87±4.46)ng/L、(49.55±6.57)ng/L、(30.22±6.37)mg/L(P<0.05);两组治疗后FVC、FEV_(1)及FEV_(1)/FVC明显上升,但观察组指标显著更优(P<0.05)。结论止咳平喘十二味合剂联合乌苯美司胶囊能够有效优化急性加重期慢阻肺病人的氧合指数、免疫功能及炎症反应,改善病人临床症状、肺功能及运动功能,值得临床予以推广。Objective To analyze the effect of Zhike Pingchuan twelve flavor mixture combined with ubenimex capsule on oxygenation index,immune imbalance and inflammatory factors in patients with COPD during acute exacerbation.Methods Sixty patients with acute exacerbation of COPD who were admitted to Tongchuan People's Hospital from January 2019 to March 2020 were selected as the research objects.According to the random number table method,they were assigned into two groups:30 cases in the control group,orally administered with conventional treatment+ubenimex capsules(t.i.d,10 mg/time),and 30 cases in the observation group,administered additionally with Zhike Pingchuan twelve mixture(twice a day,a pack/time,taking orally half an hour after meals).Both groups underwent treatment for 8 weeks.We Observed and recorded the oxygenation index(OI),COPD assessment test(CAT)score,6-minute walking test(6-MWD),immune function indexes(including CD3^(+),CD4^(+),CD8^(+) and CD4^(+)/CD8^(+)),inflammatory factors[interleukin-8(IL-8),tumor necrosis factor alpha(TNF-α),C-reactive protein(CRP)]and lung function indicators[including forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1))and FEV_(1)/FVC],and then statistical analysis was made.Results After treatment,the OI,CAT score and 6MWD were significantly improved,which were significantly better in the observation group(P<0.05).The OI in the control group and the observation group were(221.77±20.76)and(245.65±19.76),respectively.After treatment,CD3^(+),CD4^(+) and CD4^(+)/CD8^(+) increased significantly and CD8^(+) decreased significantly in both groups,but the observation group was significantly better than the control group[CD3^(+):(0.97±0.34)vs.(1.38±0.23),CD4^(+)/CD8^(+):(60.71±4.82)%vs.(67.75±4.71)%;P<0.05].After treatment,IL-8,TNF-α and C.RP were significantly decreased in both groups,and IL-8 [(17.63±4.01) ng/L],TNF-α [(38.59±6.13) ng/L] and CRP[(15.14±2.24)mg/L]in the observation group were significantly lower than those in the control group[(22.87±4.

关 键 词：肺疾病 慢性阻塞性 中草药 止咳平喘十二味合剂 乌苯美司 氧合指数 免疫功能 

分 类 号：R563.9[医药卫生—呼吸系统]